Summary of findings 10. Paroxetine compared with fluvoxamine for depression.
| Paroxetine compared with fluvoxamine for depression | ||||||
| Patient or population: patients with depression Settings: in‐ and out‐patients Intervention: paroxetine Comparison: fluvoxamine | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Fluvoxamine | Paroxetine | |||||
| Failure to respond at endpoint (6‐12 weeks) | 466 per 1000 | 510 per 1000 (386 to 629) | OR 1.19 (0.72 to 1.94) | 261 (3 studies) | ⊕⊕⊕⊝ moderate1 | |
| Failure to respond at 1‐4 weeks | Study population | OR 0.71 (0.41 to 1.24) | 281 (3 studies) | ⊕⊕⊕⊝ moderate1 | ||
| 769 per 1000 | 703 per 1000 (577 to 805) | |||||
| Moderate | ||||||
| Failure to respond at 16‐24 weeks | See comment | See comment | Not estimable | 0 (0) | No trial reported this outcome. | |
| Failure to remit at endpoint | 752 per 1000 | 703 per 1000 (571 to 807) | OR 0.78 (0.44 to 1.38) | 261 (3 studies) | ⊕⊕⊕⊝ moderate1 | |
| SMD at endpoint | The mean SMD at endpoint in the intervention groups was 0.09 standard deviations higher (0.43 lower to 0.6 higher) | 58 (1 study) | ⊕⊕⊕⊝ moderate1 | This effect approaches zero. | ||
| Failure to complete ‐ any cause ‐ | 293 per 1000 | 285 per 1000 (183 to 416) | OR 0.96 (0.54 to 1.72) | 261 (3 studies) | ⊕⊕⊕⊝ moderate1 | |
| Participants with at least some Side Effects | 609 per 1000 | 636 per 1000 (395 to 822) | OR 1.12 (0.42 to 2.97) | 261 (3 studies) | ⊕⊕⊕⊝ moderate1 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; SMD: standardized mean difference; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Blinding stated but not tested. No information on randomisation procedures and allocation concealment.